In this article we will discuss Innova Captab GMP today’s live allotment date, allotment status, subscription status and complete review, so read it carefully before applying for this IPO.
Imp. Points
Innova Captab IPO Review
| IPO Name | Innova Captab |
| Sector | Pharmateutical |
| Issue Type | Book Built IPO |
| Market Cap | ₹2563.7 Cr. |
| IPO Size | ₹570.00 Cr. (Total 12,723,214 Share) |
| Price Band | ₹426 to ₹448 / Share |
| Face Value | ₹10 / Share |
| Lot Size | 33 Shares |
| PE Ratio | 31.64 |
| Listing On | NSE & BSE |
| GMP | Check LIVE GMP |
Indian pharmaceutical company Innova Captab’ has submitted an IPO of ₹570.00 Cr open on 21st December to 26th December with a Price band of ₹426-₹448 worth of 33 shares per lot.
Innova Captab IPO list on NSE and BSE on 29th December at 10 AM. ICICI Securities and JM Financial Limited are merchant banks and KFinTech is the registrar of this IPO.
Important Date of Innova Captab IPO
| IPO Open Date | 21 December 2023 |
| IPO Last Date | 26 December 2023 *till 4:50 PM |
| Allotment status | 27 December 2023 |
| Refund Initiate | 28 December 2023 |
| Share Credit to Demat | 28 December 2023 |
| Listing On Exchange | 29 December 2023 |
You can apply for this IPO through your Demat account from 21st December to 26th December. On 27th December you will get allotment status whether you are allotted a share or not.
Share allotment status and the latest GMP are updated on the Telegram channel so click here and Join our Telegram Channel.
Innova Captab IPO Quota Reserved
| Anchor Investor | Allotted (%) |
|---|---|
| QIB | 20% |
| S-HNI | 5% |
| B-HNI | 10% |
| Retail | 35% |
| Anchor Inveastor | 30% |
| Total | 100% |
Qualified institution buyers (QIBs) are big institutes like Mutual Funds, etc. S-HNI investors are below 10 lakh and, B-HNI invest more than 10 lakh. Anchor investor list uploaded on Telegram channel
Innova Captab IPO Lot Size
| Lots | Shares | Amount | |
|---|---|---|---|
| Retail (Min) | 1 | 33 | ₹14,784 |
| Retail (Max) | 13 | 429 | ₹192,192 |
| S-HNI (Min) | 14 | 462 | ₹206,976 |
| S-HNI (Max) | 67 | 2211 | ₹990,528 |
| B-HNI (Min) | 68 | 2244 | ₹1,005,312 |
If you are a retail investor then you can apply a minimum of 1 lot with ₹14784 (Minimum Investment)
Key factor of Innova Captab IPO
| P/E | 31.64 |
| Post P/E | 36.42 |
| ROE | 24.58% |
| ROCE | 22.61% |
| Debt/Equity | 0.85 |
| EPS | 14.16 |
| RoNW | 24.58% |
Innova Captab Company Financials
| Reserve & Surplus | June 2023 | March 2023 | March 2022 | March 2021 |
|---|---|---|---|---|
| Assets | 1,086.16 | 704.41 | 575.48 | 369.62 |
| Revenue | 234.37 | 935.58 | 803.41 | 412.03 |
| Profit | 17.59 | 67.95 | 63.95 | 34.50 |
| Borrowing | 441.90 | 235.19 | 198.18 | 45.03 |
| Reserve & Surpluss | 317.51 | 228.51 | 196.61 | 132.82 |
| Net Worth | Reserve & Surplus | 276.46 | 208.56 | 144.78 |
Innova Captab Company Overview
Founded in 2005, Innova Captab is a Pharmaceutical manufacturing company. The founder is Vinay Kumar Lohariwala. Innova Captab is involved in Three Types of business in pharmaceuticals – The first is contract development manufacturing (CDM) for the other Indian top Pharmaceutical brands. Second is manufacturing and selling under its own brand Innova Captab and third is manufacturing and sale in the international market.
Currently, Innova Captab is supplying top Indian Medicine brands like Cipla, Mankind, Glenmark, Lupin, Medley Pharmaceuticals, Eris Healthcare, Zuventus Healthcare, Ajanta Pharma, etc.
₹320 Cr. is a fresh issue IPO and ₹250 Cr. is an offer for sale. The objective of an IPO is the repayment of the loan while acquiring other companies, investing in the subsidiaries and funding the working capital requirements.
Pros and Cons
- Positive
- Wide range of products over 1100.
- The pharmaceutical industry is growing rapidly after COVID
- Mostly B2B Business with large companies, so stable customers.
- Also, Export Internationally to over 20 Countries.
- Largest CDMOs in the Indian Pharmaceutical industry.
- recently invested in Jammu and Kashmir to be exempt from GST by GoI regulations.
- Negative
- Dependent on large companies.
- competitive market
- Low margins in comparison to other pharma companies.
- dependent on China for raw materials.
Final Decision
According to the current GMP and overall company’s financials and business in pharma is a plus point for Innova Captab to invest in IPO for Listing gain as well good returns in the upcoming 2-3 years. consult your financial advisor before investing in an IPO. We are discussing based on data.
If you like this article, then share it with Your Friends.
Thankyou for this review in simple & detail